Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice

General Physiology and Biophysics

Volumn 31, Issue 3, 2012, Pages 323-333

  Sundaresan, Arjunan ^a   Harini, Ranganathan ^a   Pugalendi, Kodukkur Viswanathan ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

C57BL 6J mice; High fat diet; Metabolic syndrome; Rosiglitazone; Ursolic acid

Indexed keywords

CHOLESTEROL; FATTY ACID; FRUCTOSE BISPHOSPHATASE; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLYCOLYTIC ENZYME; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TRIACYLGLYCEROL; U 6753; UNCLASSIFIED DRUG; URSOLIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WINDIA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FATTY ACID BLOOD LEVEL; FEEDING; GLUCOSE BLOOD LEVEL; GLYCOGEN ANALYSIS; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIVER; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; CYCLOOXYGENASE INHIBITORS; DIETARY FATS; DRUG THERAPY, COMBINATION; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRITERPENES;

EID: 84867817979     PISSN: 02315882     EISSN: 13384325     Source Type: Journal    
DOI: 10.4149/gpb-2012-037     Document Type: Article

References (54)

1. Arner P. (2003): The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14, 137-145 http://dx.doi.org/10.1016/S1043-2760 (03) 00024-9 (Pubitemid 36733912)
2. Balanehru S., Nagarajan B. (1991): Protective effect of oleanolic acid and ursolic acid against lipid peroxidation. Biochem. Int. 24, 981-990.
3. Balfour J. A., Plosker G. L. (1999): Rosiglitazone. Drugs 57, 921-932 http://dx.doi.org/10.2165/00003495-199957060-00007 (Pubitemid 29313203)
4. Bancrof J. D., Gamble M. (2002): Theory and practice of histological techniaques. (5th edition, China), Churchill Livingstone
5. Brandstrup N., Kirk J. E., Brunic C. (1957): Determination of glucokinase in tissues. J. Gerontol. 12, 166-171
6. Burgi W., Briner M., Franken N., Kessler A. C. (1998): One step sandwich enzyme immunoassay for insulin using monoclonal antibodies. Clin. Biochem. 21, 311-314 http://dx.doi.org/10.1016/S0009-9120 (88) 80087-0
7. Choi J. S., Koh I. U., Jung M. H., Song J. (2007): Effects of three different conjugated linoleic acid preparations on insulin signalling, fat oxidation and mitochondrial function in rats fed a high-fat diet. Br. J. Nutr. 98, 264-275 http://dx.doi.org/10.1017/S000711450770497X (Pubitemid 47091367)
8. Cong W. N., Tao R. Y., Tian J. Y., Liu G. T., Ye F. (2008): The establishment of a novel nonalcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sciences 82, 983-990 http://dx.doi.org/10.1016/j.lfs.2008.01.022
9. De Fronzo R. A. (2004): Pathogenesis of type 2 diabetes mellitus. Med. Clin. North. Am. 88, 787-835 http://dx.doi.org/10.1016/j.mcna.2004.04.013 (Pubitemid 39090340)
10. Diamant M., Hein R. J. (2003): Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence. Drugs 63, 1373-1405 http://dx.doi.org/10. 2165/00003495-200363130-00004 (Pubitemid 36776093)
11. Ding S. Y., Shen Z. F., Chen Y. T., Sun S. J., Liu Q., Xie M. Z. (2005): Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacologica. Sinica. 26, 575-580 http://dx.doi.org/10.1111/j.1745-7254.2005.00090.x (Pubitemid 40676168)
12. Drabkin D. L., Austin J. M. (1932): Spectrophotometric constants for common haemoglobin derivatives in human, dog and rabbit blood. J. Biol. Chem. 98, 719-733
13. Evans J. L., Goldfine I. D., Maddux B. A., Grodsky G. M. (2003): Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52, 1-8 http://dx.doi.org/10.2337/ diabetes.52.1.1 (Pubitemid 36042100)
14. Falholt K., Lund B., Falholt W. (1973): An easy colorimetric method for routine determination of free fatty acids in the plasma. Clin. Chim. Acta 46, 105-111 http://dx.doi.org/10.1016/0009-8981 (73) 90016-8
15. Feldstein A. E., Canbay A., Guicciardi M. E., Higuchi H., Bronk S. F., Gores G. J. (2003): Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 39, 978-983 http://dx.doi.org/10.1016/S0168- 8278 (03) 00460-4 (Pubitemid 37523769)
16. Fiske C. H., Subbarow Y. (1925): The colorimetric determination of phosphorus. J. Biol. Chem. 66, 375-392
17. Foster J. D., Pederson B. A., Nordlie R. C. (1997): Glucose-6-phosphatase structure, regulation, and function: an update. Proc. Soc. Exp. Biol. Med. 215, 314-332
18. Friedewald W. T., Levy R. I., Fredrickson D. S. (1972): Estimation of LDL-cholesterol in the plasma, without the use of preparative ultracentrifuge. Clin. Chem. 18, 449
19. Gancedo J. M., Gancedo C. (1971): Fructose 1, 6-bisphophatase, phosphofructokinase and glucose 6-phosphate dehydrogenase from fermenting yeast and non-fermenting yeast. Arch. Microbiol. 76, 132-138 http://dx.doi.org/10. 1007/BF00411787
20. Ginsberg H., Kimmerling G., Olefsky J. M., Reaven G. M. (1975): Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J. Clin. Invest. 55, 454-461 http://dx.doi.org/10. 1172/JCI107951
21. Grundy M. (1999): Hypertriglyceridemia, insulin resistance, and metabolic syndrome. Am. J. Cardiol. 83, 25F-29 http://dx.doi.org/10.1016/S0002-9149 (99) 00211-8
22. Guignot L., Mithieux G. (1999): Mechanisms by which insulin, associated or not with glucose, may inhibit hepatic glucose production in the rat. Am. J. Physiol. 277, 984-989
23. Jayaprakasam B., Olson L. K., Schutzki R. E., Tai M. H., Nair G. M. (2006): Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). J. Agric. Food Chem. 54, 243-248 http://dx.doi.org/10.1021/jf0520342 (Pubitemid 43119946)
24. Koide H., Oda T. (1959): Pathological occurrence of glucose 6-phosphatase in serum in liver diseases. Clin. Chim. Acta 4, 554 http://dx.doi.org/10.1016/ 0009-8981 (59) 90165-2
25. Kolovou G. D., Anagnostopoulou K. K., Cokkinos D. V. (2005): Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad. Med. J. 81, 358-366 http://dx.doi.org/10.1136/pgmj.2004.025601 (Pubitemid 40834900)
26. Lim S., Yoonk J. W., Choi S. H., Cho B. J., Kim J. T., Chang H. S., Park H. S., Park K. S., Lee H. K., Kim Y. B., Jang H. C. (2009): Effectofginsam, avinegar extract from Panax ginseng, onbody weight and glucose homeostasis in an obese insulin-resistant rat model. Metabolism 58, 8-15 http://dx.doi.org/10. 1016/j.metabol.2008.07.027
27. Liu J. (1995): Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49, 57-68 http://dx.doi.org/10.1016/0378-8741 (95) 90032-2 (Pubitemid 26010740)
28. Lowell B. B. (1999): PPAR: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99, 239-242 http://dx.doi.org/10.1016/ S0092-8674 (00) 81654-2 (Pubitemid 29519902)
29. Masoudi F. A., Wang Y., Inzucchi S. E., Setaro J. F., Havranek E. P., Foody J. M., Krumholz H. M. (2003): Metformin and thiazolidinedione use in medicare patients with heart failure. JAMA. 290, 81-88 http://dx.doi.org/10. 1001/jama.290.1.81 (Pubitemid 37432869)
30. Monnier L., Colette C., Percheron C., Descomps B. (1995): Insulin, diabetes and cholesterol metabolism. C. R. Seances Soc. Biol. Fil. 189, 919-931
31. Morales M. A., Jabbagy A. J., Terenzi H. P. (1975): Mutations affecting accumulation of glycogen. Neurospora. News Lett. 20, 24-25
32. Petersen K. F., Shulman G. I. (2006): Etiology of insulin resistance. Am. J. Med. 119, S10-16 http://dx.doi.org/10.1016/j.amjmed.2006.01.009
33. Polonsky K. S., Given B. D., Hirsch L., Shapiro E. T., Tillil H., Beebe C., Galloway J. A., Frank B. H., Karrison T., Van Cauter E. (1988): Quantitative study of insulin secretion and clearance in normal and obese subjects. J. Clin. Invest. 81, 435-441 http://dx.doi.org/10.1172/JCI113338 (Pubitemid 18075237)
34. Postic C., Shiota M., Niswender K. D., Jetton T. L., Chen Y., Moates J. M., Shelton K. D., Lindner J., Cherrington A. D., Magnuson M. A. (1999): Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knockouts using Cre recombinase. J. Biol. Chem. 274, 305-315 http://dx.doi.org/10.1074/jbc.274.1.305 (Pubitemid 29035064)
35. Proietto J. (2005): Mechanisms of insulin resistance caused by nutrient toxicity. Hepatol. Res. 33, 87-91 http://dx.doi.org/10.1016/j.hepres.2005.09.010 (Pubitemid 41799781)
36. Riemens S. C., Sluiter W. J., Dullaart R. P. (2000): Enhanced escape of non-esterified fatty acids from tissue uptake: its role in impaired insulin-induced lowering of total rate of appearance in obesity and type 2 diabetes mellitus. Diabetologia 43, 416-426 http://dx.doi.org/10.1007/ s001250051324 (Pubitemid 30237949)
37. Saravanan R., Pugalendi K. V. (2006): Impact of ursolic acid on chronic ethanol-induced oxidative stress in the rat heart. Pharmacol. Rep. 58, 41-47
38. Sasaki T., Matsy S., Sonac A. (1972): Effect of acetic and concentration on the colour reaction in the O-toluidine boric acid method for blood glucose estimation. Rinsho Kagaku 1, 346-353
39. Scheen A. J. (2005): Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 28, 601-631 http://dx.doi.org/ 10.2165/00002018-200528070-00004 (Pubitemid 41003048)
40. Schrauwen-Hinderling V. B., Kooi M. E., Hesselink M. K., Moonen-Kornips E., Schaart G., Mustard K. J., Hardie D. G., Saris W. H., Nicolay K. (2005): Intramyocellular lipid content molecular adaptations in response to a 1-week high-fat diet. Obes. Res. 13, 2088-2094 http://dx.doi.org/10.1038/oby.2005.259
41. Semenkovich C. F. (2006): Insulin resistance and atherosclerosis. J. Clin. Invest. 116, 1813-1822 http://dx.doi.org/10.1172/JCI29024 (Pubitemid 44033301)
42. Senthil S., Chandramohan G., Pugalendi K. V. (2007): Isomers (oleanolic acid ursolic acids) differ in their protective effect against isoproterenol-induced myocardial schemic in rats. Int. J. Cardiol. 119, 131-133 http://dx.doi.org/10.1016/j.ijcard.2006.07.108 (Pubitemid 46818488)
43. Sohn K. H., Lee H. Y., Chung H. Y., Young H. S., Yi S. Y., Kim K. W. (1995): Anti-angiogenic activity of triterpene acids. Cancer Lett. 94, 213-218 http://dx.doi.org/10.1016/0304-3835 (95) 03856-R
44. Somova L. O., Nadar A., Rammanan P., Shode F. O. (2003): Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 10, 115-121 http://dx.doi.org/10.1078/ 094471103321659807 (Pubitemid 36433204)
45. Sowers J. R. (2004): Insulin resistance and hypertension. Am. J. Physiol. Heart. Circ. Physiol. 286, H1597-1602 http://dx.doi.org/10.1152/ajpheart.00026. 2004 (Pubitemid 38525443)
46. Steinbrecher U. P., Witztum J. L. (1984): Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 33, 130-134 http://dx.doi.org/10.2337/diabetes.33.2.130 (Pubitemid 14184698)
47. Sudhakar N. S., Pattabiraman T. N. (1981): A new colorimetric method for the estimation of glycosylated haemoglobin. Clin. Chim. Acta 109, 267-274 http://dx.doi.org/10.1016/0009-8981 (81) 90312-0 (Pubitemid 11165574)
48. Surwit R. S., Kuhn C. M., Cochrane C., McCubbin J. A., Feinglos M. N. (1998): Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37, 1163-1167 http://dx.doi.org/10.2337/diabetes.37.9.1163
49. Tahara Y., Shima K. (1995): Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 18, 440-447 http://dx.doi.org/10.2337/diacare.18. 4.440
50. Taskinen M. R., Beltz W. F., Harper I., Fields R. M., Schonfeld G., Grundy S. M., Howard B. V. (1986): Effects of NIDDM on very-low-density lipoprotein triglyceride and apo-lipoprotein B metabolism. Studies before and afer sulfonylurea therapy. Diabetes 35, 1268-1277 http://dx.doi.org/10.2337/ diabetes.35.11.1268 (Pubitemid 17186523)
51. Vidal-Puig A. J., Considine R. V., Jimenez-Liñan M., Werman A, Pories W. J., Caro J. F., Flier J. S. (1977): Peroxisome proliferator-activated receptor gene expression in human tissues Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99, 2416-2422 http://dx.doi.org/10.1172/JCI119424
52. Wu L., Wang R., De Champlain J., Wilson T. W. (2004): Beneficialand deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am. J. Hypertens. 17, 749-756 http://dx.doi.org/10.1016/j.amjhyper.2004.04.010 (Pubitemid 39201088)
53. Yip J., Facchini F. S., Reaven G. M. (1998): Resistance to insulinmediated glucose disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab. 83, 2773-2776 http://dx.doi.org/10.1210/jc.83.8.2773 (Pubitemid 28493774)
54. Zhang W., Hong D., Zhou Y., Zhang Y., Shen Q., Li J. Y., Hu L. H., Li J. (2006): Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim. Biophys. Acta 1760, 1505-1512 http://dx.doi.org/10.1016/j.bbagen. 2006.05.009 (Pubitemid 44428024)